Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia

Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common mechanism of resistance is the acquisition of a point mutation in the BCR-ABL kinase domain. Few studies have reported African patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadesse, Fisihatsion, Asres, Getahun, Abubeker, Abdulaziz, Gebremedhin, Amha, Radich, Jerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457809/
https://www.ncbi.nlm.nih.gov/pubmed/34292760
http://dx.doi.org/10.1200/GO.21.00058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457809/
https://www.ncbi.nlm.nih.gov/pubmed/34292760
http://dx.doi.org/10.1200/GO.21.00058

Ejemplares similares